The New Question in Health AI: Was It Tested on Children?
Research Horizons raises a basic but increasingly urgent issue: whether an AI tool was ever evaluated in children before being used in pediatric care. The concern is not just ethical oversight, but whether models trained on adult data can safely generalize to younger patients.
Pediatric AI is often treated as an extension of general healthcare AI, but that assumption can be dangerous. Children are not simply smaller adults: anatomy, physiology, disease presentation, and imaging patterns can differ substantially, which means model performance in adults may not translate cleanly to pediatric populations.
This article taps into a broader accountability gap in healthcare AI. Many tools reach clinical settings with limited demographic transparency, and pediatric validation is especially easy to miss because children represent smaller datasets and are less attractive to commercial developers. That creates a risk that some of the most vulnerable patients are the least well represented in AI evaluation.
The most important implication is regulatory and operational. Health systems should be asking vendors not only for accuracy metrics, but for age-stratified validation, failure mode analysis, and explicit pediatric labeling where appropriate. In a field that already struggles with generalizability, “tested in children” should become a standard procurement question, not an afterthought.
Ultimately, the piece is a reminder that healthcare AI safety is not one-size-fits-all. If an AI product cannot demonstrate performance in the population where it will be used, then it is not ready for routine deployment there.